Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651272 · ClinicalTrials.gov registry record · Phase 2
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
A Phase 2 study, sponsored by Boston University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02651272: Clinical Trial Phase 2 study, sponsored by Boston University.
NCT02651272 is a Phase 2 study that was terminated before completion, run by Boston University. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02651272, a Phase 2 study, was terminated before completion, sponsored by Boston University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.
Primary Outcome
The occurrence of treatment emergent AEs includes having any of the following: vaso-occlusive crises requiring hospitalization; acute congestive heart failure; hypotension (defined as a mean arterial pressure less than 60mmHg); decrease in hemoglobin concentration by greater than 1 g/dL.
Interventions
- DRUG macitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 2 |
Why NCT02651272 stopped before completion
NCT02651272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which macitentan is the first listed.
NCT02651272 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02651272 about?
NCT02651272 is a clinical study titled "Macitentan in Pulmonary Hypertension of Sickle Cell Disease". This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.
What is the current status of trial NCT02651272?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-07. Estimated completion is 2019-12-18.
What interventions are being tested in trial NCT02651272?
The interventions under investigation include: macitentan (DRUG).
Who is sponsoring clinical trial NCT02651272?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02651272's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia